4.5 Article

Breast Cancer, Version 1.2016 Featured Updates to the NCCN Guidelines

期刊

出版社

HARBORSIDE PRESS
DOI: 10.6004/jnccn.2015.0176

关键词

-

类别

资金

  1. Eisai
  2. Bristol-Myers Squibb
  3. Genentech BioOncology
  4. Merck
  5. Novartis Oncology
  6. Novocure
  7. Boehringer Ingelheim Pharmaceuticals, Inc.

向作者/读者索取更多资源

These NCCN Guideline Insights highlight the important updates to the systemic therapy recommendations in the 2016 NCCN Guidelines for Breast Cancer. In the most recent version of these guidelines, the NCCN Breast Cancer Panel included a new section on the principles of preoperative systemic therapy. In addition, based on new evidence, the panel updated systemic therapy recommendations for women with hormone receptor-positive breast cancer in the adjuvant and metastatic disease settings and for patients with HER2-positive metastatic breast cancer. This report summarizes these recent updates and discusses the rationale behind them.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据